Bazedoxifene is a non-steroidal, orally active, selective estrogen receptor regulator capable of acting on ERα (IC50:26 nM) and ERβ (IC50:99 nM) for the study of osteoporosis in postmenopausal women. It is also an IL-6/GP130 protein interaction inhibitor that can be used to study pancreatic cancer.